Clinical development through phase III in fluorescence-guided surgery: the story of SGM-101, an anti-CEA antibody conjugate, paving the way for a new wave of surgical products

Françoise Cailler

doi:10.1117/12.2619284

7 March 2022 Clinical development through phase III in fluorescence-guided surgery: the story of SGM-101, an anti-CEA antibody conjugate, paving the way for a new wave of surgical products

Françoise Cailler

Author Affiliations +

Proceedings Volume PC11943, Molecular-Guided Surgery: Molecules, Devices, and Applications VIII; PC119430H (2022) https://doi.org/10.1117/12.2619284
Event: SPIE BiOS, 2022, San Francisco, California, United States

Abstract

This Conference Presentation, “Clinical development through phase III in fluorescence-guided surgery: the story of SGM-101, an anti-CEA antibody conjugate, paving the way for a new wave of surgical products” was recorded at SPIE Photonics West 2022 held in San Francisco, California, United States.

Conference Presentation

Citation Download Citation

Françoise Cailler "Clinical development through phase III in fluorescence-guided surgery: the story of SGM-101, an anti-CEA antibody conjugate, paving the way for a new wave of surgical products", Proc. SPIE PC11943, Molecular-Guided Surgery: Molecules, Devices, and Applications VIII, PC119430H (7 March 2022); https://doi.org/10.1117/12.2619284

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available